Table of Contents
A patent infringement analysis Research Triangle matter is unusual before a single claim is even read, because the Triangle does not sit inside one federal court. Raleigh, Durham and Chapel Hill span two of North Carolina’s three federal judicial districts, and Research Triangle Park itself straddles the county line that divides them. That single fact shapes where a case can be filed, which procedural rules govern the claim chart, and how quickly an accused product moves from a demand letter to a scheduling order. We build the technical analysis with those forks already mapped, so the read that lands on a partner’s desk is ready for whichever courtroom the venue statute actually allows.
Why a patent infringement analysis Research Triangle case answers to two federal courts
Start with the map, because it catches out even experienced litigators who assume “the Triangle” is one place. Raleigh sits in Wake County, which falls in the U.S. District Court for the Eastern District of North Carolina (EDNC), headquartered in Raleigh and serving 44 counties from the capital to the Atlantic coast. Wake County sits in the EDNC’s Western Division.
Durham and Chapel Hill are a different story. Durham County and Orange County both fall inside the U.S. District Court for the Middle District of North Carolina (MDNC), which is headquartered in Greensboro and also sits in Winston-Salem and Durham. So a company in downtown Durham and a company ten miles away in Raleigh answer to two separate federal courts, with two separate clerks, two sets of judges and, as we will see, two very different attitudes to patent procedure.
Research Triangle Park makes the split concrete. The park itself is physically divided between Durham County and Wake County, which means a single research campus can sit astride the EDNC/MDNC boundary. Where an accused product is designed, made or sold inside RTP can therefore decide which district hears the case. That is not a trivia point; under the venue statute it can be dispositive, and it is the first thing our analysis flags for Triangle counsel.
TC Heartland and where a Triangle defendant can actually be sued
Since the Supreme Court’s 2017 decision in TC Heartland LLC v. Kraft Foods, patent venue is governed strictly by 28 U.S.C. section 1400(b), not the general venue statute. A domestic corporation can be sued for patent infringement only (i) in the judicial district where it is incorporated, or (ii) where it has committed acts of infringement and has a regular and established place of business.
For a Triangle defendant that means the analysis has to be geographically precise. A Delaware-incorporated biotech with a plant in Durham “resides” in Delaware for venue, but can also be sued in the MDNC if the accused acts and a fixed place of business are both there. Move that plant across the county line into Wake County and the proper district becomes the EDNC instead. The Federal Circuit’s In re Cray framework — a physical place, that is regular and established, and that is the defendant’s — governs the second prong.
This is why our Patent Infringement Analysis for Triangle clients ties each accused act to a physical location, not just a corporate name. Where the same product is developed in RTP and sold statewide, we identify every district that could plausibly hold venue, because a plaintiff’s choice between the EDNC and the MDNC changes the local rules, the judge pool and the realistic time to trial. Getting the map wrong invites a transfer motion under 28 U.S.C. section 1406 or 1404 before the merits are ever reached.
The Middle District’s dedicated patent rules, and what the Eastern District does differently
The two courts are not procedurally symmetrical, and this is the single most practical reason to know which side of the county line a matter falls on. The MDNC has adopted a dedicated set of Local Patent Rules, most recently amended effective 8 February 2021. They impose a structured, front-loaded disclosure sequence: infringement contentions, invalidity contentions, claim-construction exchanges, opinion-of-counsel disclosures, and expert discovery all run on court-mandated deadlines.
For an accused party in Durham or Chapel Hill, that changes the economics of the case. A patentee must serve detailed infringement contentions early — an element-by-element read of the asserted claims against the accused product — and a defendant must answer with equally detailed invalidity contentions on a fixed clock. The technical analysis cannot be improvised the week before a deadline; it has to be litigation-grade from the outset. Our claim charts are built to slot directly into that MDNC disclosure schedule.
The EDNC, covering Raleigh and Wake County, does not run the same specialized patent-rules regime, so patent cases there proceed under the court’s general civil practice and the presiding judge’s scheduling order. That gives more room to shape the sequence, but less certainty about deadlines. A patentee weighing a Raleigh filing against a Durham filing is, in effect, choosing between a predictable disclosure ladder and a more discretionary schedule — and the strength of the underlying prior art & litigation search often decides which trade-off favours the client.
Beyond the district court: PTAB review, the ITC and the Federal Circuit
A Triangle infringement dispute rarely lives in one forum. Whichever district hears the case, appeals on patent issues do not go to the Fourth Circuit in Richmond — they go exclusively to the U.S. Court of Appeals for the Federal Circuit in Washington, which unifies patent law nationwide. An analysis built for the EDNC or MDNC therefore has to anticipate a Federal Circuit standard of review, particularly on claim construction.
The Patent Trial and Appeal Board (PTAB) runs a parallel track. An accused party in RTP can petition for inter partes review at the USPTO to challenge the asserted patent’s validity on prior-art grounds, often while the district case is pending. IPR uses a different claim-construction standard’s cousin and a preponderance burden, and a district judge may stay the litigation while the PTAB proceeds. A serious analysis weighs the district read and the IPR read together, because the same claim term can win in one forum and lose in the other.
The third route matters for the Triangle’s manufacturers and importers. The U.S. International Trade Commission hears Section 337 investigations targeting imported articles that infringe a U.S. patent, and its remedy is an exclusion order barring goods at the border — powerful for a domestic biomanufacturer facing imported competition. Section 337 has a domestic-industry requirement and a punishing schedule, so the infringement and validity analysis has to be complete before a complaint is filed, not after. Where invalidity is the stronger play, we hand off to a full patent invalidation workstream.
What the Triangle’s industries put in front of an infringement read
The Research Triangle is not a generic litigation market; its technology mix drives the kind of infringement analysis that lands here. Life sciences dominate. Biogen is investing roughly $2 billion to expand manufacturing across its two RTP campuses, and GSK, Novo Nordisk and Eli Lilly all run significant Triangle operations. North Carolina’s life-sciences workforce passed 100,000 jobs in 2023, and much of it clusters here.
That produces infringement questions that are chemical and biological, not mechanical: formulation and dosage claims, antibody and biologic sequence claims, cell-culture and bioprocessing method claims, and manufacturing-process patents where the alleged infringement happens inside a bioreactor no competitor can inspect. Reading those claims demands doctrine-of-equivalents analysis and, frequently, an inference from the product back to the process. A patent infringement analysis Research Triangle biomanufacturers can act on has to reason about what the accused facility must be doing, not only what its label says.
Agtech is the second pillar. BASF is expanding its RTP plant-science campus and Bayer Crop Science runs major operations in the region, generating seed-trait, gene-editing and crop-protection patents whose claims blend biology and chemistry. Software and IT are the third: SAS in Cary, IBM, and Red Hat in downtown Raleigh anchor a cluster whose claims turn on functional and means-plus-function limitations, source-code review and Section 101 eligibility exposure.
The fourth strand is university spin-outs. Duke in Durham, UNC-Chapel Hill in Orange County, and NC State in Raleigh feed a steady pipeline of licensed inventions, and enforcement often begins from a university-owned patent asserted by an exclusive licensee. Notably, Duke and UNC sit in the MDNC while NC State sits in the EDNC — the district split reaches straight into the region’s research base.
How the claim chart gets built for a Triangle matter
The deliverable that decides an infringement dispute is the claim chart, and we build it the same way whether the target forum is Raleigh, Durham or the PTAB. First, claim construction: we fix the ordinary meaning of every asserted term, flag the ones a court will have to construe, and note where the specification or prosecution history narrows scope. A term that reads on the accused product broadly and survives an invalidity attack narrowly is where most Triangle cases are won or lost.
Second, the element-by-element read. Each limitation of each asserted claim is mapped to a specific feature of the accused product or process, with the evidence cited — a datasheet, a label, a teardown, a genome or a source-code excerpt. Where a literal element is missing, we assess the doctrine of equivalents and the prosecution-history estoppel that may bar it. This is the read that MDNC infringement contentions demand and that an EDNC scheduling order will eventually require.
Third, the validity overlay. An infringement read is only worth acting on if the claim survives the prior art, so we pair it with a search that anticipates the invalidity contentions the other side will serve. A complete patent infringement analysis Research Triangle counsel can file with therefore arrives as a matched pair — infringement and validity — because that is how the case will actually be litigated.
Working with Triangle counsel and in-house teams
Most Triangle work reaches us in one of two postures: a demand letter or complaint that needs a fast non-infringement and invalidity read, or a pre-suit assessment where a patentee wants to know whether a case is worth filing and in which district. Both are routine. We work from issued patents and their file histories, accused-product samples and documentation, published sequences, and technical literature, and we return charts in the format the receiving forum expects.
Because the region straddles the EDNC and MDNC, we deliver venue-aware. The analysis identifies which districts can hold venue under section 1400(b), whether the MDNC’s Local Patent Rules will govern the disclosure clock, and whether a parallel IPR or Section 337 action changes the calculus. For a matter that could land in either federal court, that mapping is done before the technical read is finalized, not bolted on afterward.
A quick checklist we run on every Triangle matter before the analysis leaves our desk:
- Venue is pinned to a place, not a name. Every accused act is tied to a physical location so the EDNC-versus-MDNC question is answered on facts, not assumptions.
- Each claim element is charted to evidence. No limitation is asserted without a cited datasheet, label, sequence or code reference.
- The doctrine of equivalents is addressed, not assumed. Missing literal elements are analysed for equivalents and for estoppel that would bar them.
- Validity is read alongside infringement. The prior art that will feed the other side’s invalidity contentions is searched up front.
- Parallel forums are scoped. The PTAB and ITC options are assessed before a district complaint is drafted.
- The Federal Circuit standard is anticipated. Claim construction is built to survive de novo review, because that is where a patent appeal goes.
For the wider U.S. picture — other districts, other industries and the firm’s cross-border reach — see our United States IP hub.
IP Landscape & Resources in Research Triangle
Key intellectual-property authorities and venues relevant to Research Triangle:
- U.S. District Court, Middle District of North Carolina — the court covering Durham and Chapel Hill, with dedicated Local Patent Rules governing infringement and invalidity contentions
- U.S. District Court, Eastern District of North Carolina — the Raleigh-headquartered court covering Wake County, where patent cases run under the general civil rules and the judge's scheduling order
- United States Patent and Trademark Office (USPTO) — grants the patents at issue and houses the PTAB, which conducts inter partes review of validity
- U.S. International Trade Commission (USITC) — hears Section 337 investigations and can issue exclusion orders against infringing imported articles
Request a Patent Infringement Analysis Consultation in the Research Triangle
Request a Patent Infringement Analysis Consultation in the Research Triangle
Send us the patent, the accused product and the venue in play across the EDNC and MDNC. We will scope a venue-aware infringement and validity read for your Raleigh, Durham or RTP matter before any work begins.
Explore related PerspireIP services: Patent Infringement Analysis · patent invalidation · prior art & litigation search · our United States IP hub.
Frequently Asked Questions
Which federal court hears a patent case in the Research Triangle?
It depends on the city. Raleigh (Wake County) sits in the Eastern District of North Carolina, while Durham and Chapel Hill (Durham and Orange counties) sit in the Middle District of North Carolina. Research Triangle Park itself is split between Durham and Wake counties, so a single campus can straddle the EDNC/MDNC line, and the accused activity’s location can decide the district.
How does TC Heartland affect where a Triangle company can be sued for infringement?
Under TC Heartland and 28 U.S.C. section 1400(b), a domestic corporation can be sued for patent infringement only where it is incorporated or where it has both committed acts of infringement and maintains a regular and established place of business. For Triangle defendants that ties venue to a specific physical location, which is why our analysis pins every accused act to a place, not just a corporate name.
Are the Eastern and Middle Districts of North Carolina procedurally different for patent cases?
Yes, and materially. The Middle District has adopted dedicated Local Patent Rules (amended effective 8 February 2021) that set a fixed schedule for infringement contentions, invalidity contentions and claim construction. The Eastern District runs patent cases under its general civil rules and the presiding judge’s scheduling order, so the disclosure timeline is more discretionary.
Can I challenge the patent at the USPTO instead of, or alongside, a Triangle lawsuit?
Yes. An accused party can file an inter partes review petition at the PTAB to attack the patent’s validity on prior-art grounds, often in parallel with the district case, and a judge may stay the litigation while the PTAB proceeds. Because the district and IPR forums apply different standards and burdens, we analyse both together rather than in isolation.
What industries in the Research Triangle most often need an infringement analysis?
Biopharma and biomanufacturing lead — companies like Biogen, GSK and Novo Nordisk generate formulation, biologic and bioprocessing claims. Agtech (BASF plant science, Bayer Crop Science), software and IT (SAS, IBM, Red Hat), and university spin-outs from Duke, UNC-Chapel Hill and NC State round out the mix, each raising distinct claim-reading challenges.
Where do patent appeals from North Carolina go?
Not to the Fourth Circuit. Appeals on patent issues from any U.S. district court, including the EDNC and MDNC, go exclusively to the U.S. Court of Appeals for the Federal Circuit in Washington, which reviews claim construction de novo. We build the analysis to that standard from the start.